When You Hear "It's Attached to the Aorta, So Surgery Isn't Possible": How Adhesion and Invasion Differ on Imaging, and When Surgery Can Return to the Table

One of the heaviest sentences a family can hear in a gastric cancer clinic is that the tumor is "stuck to a major blood vessel, so we cannot remove it right now." Central vessels such as the aorta, celiac artery, or superior mesenteric artery generally cannot be resected and reconstructed, so when a tumor appears to encase them, the situation is classified as technically unresectable. Families often hear this as "terminal," but unresectability has at least three distinct causes: distant spread such as metastasis or peritoneal seeding; locally advanced disease that invades major vessels or retroperitoneal structures without distant spread; and cases where the disease itself might be removable but the person's heart, lung, or nutritional status makes major surgery unsafe. Each path leads to a different next step, so it is worth asking which of these applies.

The phrase "attached to" is less precise on imaging than it sounds. Radiologists estimate invasion by looking at whether the fat plane between tumor and vessel has disappeared and how much of the vessel circumference is in contact, but inflammation or long-standing adhesion can look identical to true tumor invasion on a scan. That is why reports often say "suspicious for" or "cannot be excluded." This is not a sign of a poor-quality study; it reflects the honest limit of what imaging can resolve. Practically, it means an unresectable call describes this moment, based on today's scan and today's condition — not a permanent verdict.

This is where the goal of chemotherapy matters. In locally advanced gastric cancer without distant metastasis, one common path is to give several cycles of induction or neoadjuvant chemotherapy, repeat imaging, and reopen the surgical discussion if the tumor shrinks enough to restore a margin around the vessel. Operating on a patient initially judged inoperable is called conversion surgery. It is not available to everyone; response to treatment, the location of remaining disease, overall fitness, and nutrition all weigh in. Still, "the mass is large, so chemotherapy is pointless" and "chemotherapy may not get us to an operation" are different statements. Asking directly whether the aim of this regimen is symptom control, slowing progression, or pursuing resectability makes every later decision clearer.

Before treatment starts, tissue from the biopsy is often tested for markers that can change the drug combination — HER2 expression, microsatellite instability (MSI) or mismatch repair deficiency (dMMR), and PD-L1 expression among them. Results can take time, and the first cycle sometimes begins before they return, so it helps to ask whether testing is underway and whether the plan could change once it is back.

Age alone does not decide whether treatment is offered. Teams weigh walking ability, recent weight change, kidney and liver function, other conditions and medications, and how independently the person lives. Starting with fewer drugs or a reduced dose and adjusting by response and side effects is a way of finding a regimen that can actually be completed, not a way of giving up.

While the plan is being made, a few things are worth tracking at home: weight measured under similar conditions each day, how much of a meal is actually finished, whether food feels like it catches on the way down, any black stools or vomiting of blood, and fever — each noted with the date. Gastric tumors can bleed or obstruct suddenly, so dizziness with cold sweats, or an inability to keep anything down, are generally treated as reasons to seek care immediately rather than waiting for the next appointment. Bringing four questions to the clinic — why resection is difficult, when and how response will be reassessed, whether surgery could be reconsidered if things improve, and what the plan is if eating becomes blocked — makes a short consultation go much further.

This article is general health information and does not replace individual diagnosis or treatment. Staging and treatment plans depend on imaging, pathology, and overall condition, so please discuss any decisions with your own medical team.